Cargando…

Tear biomarkers in latanoprost and bimatoprost treated eyes

PURPOSE: Prostaglandin analogues (PGA’s) are the mainstay and first line of treatment in current glaucoma practise. Though latanoprost and bimatoprost are the most commonly used PGA’s with minimal side effects at lower concentrations like bimaotoprost 0.01%, direct comparison of their cytokine/MMP p...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Shweta, Sahay, Prity, Padhy, Debananda, Sarangi, Sarada, Suar, Mrutyunjay, Modak, Rahul, Rao, Aparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078293/
https://www.ncbi.nlm.nih.gov/pubmed/30080906
http://dx.doi.org/10.1371/journal.pone.0201740
_version_ 1783345065659203584
author Reddy, Shweta
Sahay, Prity
Padhy, Debananda
Sarangi, Sarada
Suar, Mrutyunjay
Modak, Rahul
Rao, Aparna
author_facet Reddy, Shweta
Sahay, Prity
Padhy, Debananda
Sarangi, Sarada
Suar, Mrutyunjay
Modak, Rahul
Rao, Aparna
author_sort Reddy, Shweta
collection PubMed
description PURPOSE: Prostaglandin analogues (PGA’s) are the mainstay and first line of treatment in current glaucoma practise. Though latanoprost and bimatoprost are the most commonly used PGA’s with minimal side effects at lower concentrations like bimaotoprost 0.01%, direct comparison of their cytokine/MMP profile in tears has not been evaluated earlier. The study intends to ascribe PGA to the upregulation of MMPs, Cytokines and Chemokines mediating varied pathways to result in side effects of the drugs. METHODS: Tear sample collection was done from outer canthus of 30 eyes of 30 patients (primary open angle glaucoma (n = 26 and n’ = 20), normal tension glaucoma (n = 4 and n’ = 10), in latanoprost (n) 0.005% and bimatoprost (n’) 0.01% group respectively, with a mean age of 62±10.5 years) on >6 months of PGA use using Tear flo(TM) Schirmer filter strip. Tear samples from 30 eyes of 30 cataract patients without drug treatment were used as the control. Gelatinolytic activity of MMP-9 and MMP-2 were examined by substrate gelatine zymography MMP-1 and TIMP-1 concentrations from tears samples with PGAs were evaluated by ELISA while cytokine concentration in the eluted tears was evaluated using a convenient bioplex kit assay (Milliplex MAP kit, HCYTMAG-60K-PX41, Millipore, Massachusetts, United States). The mean duration of use of PGA in both groups did not differ significantly (median 1.3 years in bimatoprost and 1.1 years in latanoprost eyes, p = 0.6). RESULTS: The tear MMP-9 expression was higher in eyes receiving latanoprost while the MMP-2 expression was higher in eyes receiving bimatoprost with MMP1 protein levels being higher in the former. Latanoprost treated eyes had marginally elevated tear cytokines involved in tissue remodelling while bimatoprost eyes showed elevated cytokines regulating allergic pathways. CONCLUSION: Differential cytokine and MMP expression indicates differential signalling pathways mediating different cellular effects (evident as clinical and side effects) with the two drugs which can be explored further.
format Online
Article
Text
id pubmed-6078293
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-60782932018-08-28 Tear biomarkers in latanoprost and bimatoprost treated eyes Reddy, Shweta Sahay, Prity Padhy, Debananda Sarangi, Sarada Suar, Mrutyunjay Modak, Rahul Rao, Aparna PLoS One Research Article PURPOSE: Prostaglandin analogues (PGA’s) are the mainstay and first line of treatment in current glaucoma practise. Though latanoprost and bimatoprost are the most commonly used PGA’s with minimal side effects at lower concentrations like bimaotoprost 0.01%, direct comparison of their cytokine/MMP profile in tears has not been evaluated earlier. The study intends to ascribe PGA to the upregulation of MMPs, Cytokines and Chemokines mediating varied pathways to result in side effects of the drugs. METHODS: Tear sample collection was done from outer canthus of 30 eyes of 30 patients (primary open angle glaucoma (n = 26 and n’ = 20), normal tension glaucoma (n = 4 and n’ = 10), in latanoprost (n) 0.005% and bimatoprost (n’) 0.01% group respectively, with a mean age of 62±10.5 years) on >6 months of PGA use using Tear flo(TM) Schirmer filter strip. Tear samples from 30 eyes of 30 cataract patients without drug treatment were used as the control. Gelatinolytic activity of MMP-9 and MMP-2 were examined by substrate gelatine zymography MMP-1 and TIMP-1 concentrations from tears samples with PGAs were evaluated by ELISA while cytokine concentration in the eluted tears was evaluated using a convenient bioplex kit assay (Milliplex MAP kit, HCYTMAG-60K-PX41, Millipore, Massachusetts, United States). The mean duration of use of PGA in both groups did not differ significantly (median 1.3 years in bimatoprost and 1.1 years in latanoprost eyes, p = 0.6). RESULTS: The tear MMP-9 expression was higher in eyes receiving latanoprost while the MMP-2 expression was higher in eyes receiving bimatoprost with MMP1 protein levels being higher in the former. Latanoprost treated eyes had marginally elevated tear cytokines involved in tissue remodelling while bimatoprost eyes showed elevated cytokines regulating allergic pathways. CONCLUSION: Differential cytokine and MMP expression indicates differential signalling pathways mediating different cellular effects (evident as clinical and side effects) with the two drugs which can be explored further. Public Library of Science 2018-08-06 /pmc/articles/PMC6078293/ /pubmed/30080906 http://dx.doi.org/10.1371/journal.pone.0201740 Text en © 2018 Reddy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Reddy, Shweta
Sahay, Prity
Padhy, Debananda
Sarangi, Sarada
Suar, Mrutyunjay
Modak, Rahul
Rao, Aparna
Tear biomarkers in latanoprost and bimatoprost treated eyes
title Tear biomarkers in latanoprost and bimatoprost treated eyes
title_full Tear biomarkers in latanoprost and bimatoprost treated eyes
title_fullStr Tear biomarkers in latanoprost and bimatoprost treated eyes
title_full_unstemmed Tear biomarkers in latanoprost and bimatoprost treated eyes
title_short Tear biomarkers in latanoprost and bimatoprost treated eyes
title_sort tear biomarkers in latanoprost and bimatoprost treated eyes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078293/
https://www.ncbi.nlm.nih.gov/pubmed/30080906
http://dx.doi.org/10.1371/journal.pone.0201740
work_keys_str_mv AT reddyshweta tearbiomarkersinlatanoprostandbimatoprosttreatedeyes
AT sahayprity tearbiomarkersinlatanoprostandbimatoprosttreatedeyes
AT padhydebananda tearbiomarkersinlatanoprostandbimatoprosttreatedeyes
AT sarangisarada tearbiomarkersinlatanoprostandbimatoprosttreatedeyes
AT suarmrutyunjay tearbiomarkersinlatanoprostandbimatoprosttreatedeyes
AT modakrahul tearbiomarkersinlatanoprostandbimatoprosttreatedeyes
AT raoaparna tearbiomarkersinlatanoprostandbimatoprosttreatedeyes